http://rdf.ncbi.nlm.nih.gov/pubchem/reference/27119973

Outgoing Links

Predicate Object
contentType Journal Article|Research Support, Non-U.S. Gov't
endingPage 2457
issn 0741-238X
1865-8652
issueIdentifier 5
pageRange 2447-2457
publicationName Advances in Therapy
startingPage 2447
hasFundingAgency http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_0a983ed22c023574e678532a4d684154
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_776ec35695b1ee5fe638577acdd62453
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_2e0e437c0e4af165257732d133128cb6
bibliographicCitation Peng Y, Zeng X, Peng L, Liu Q, Yi L, Luo X, Li S, Wang L, Qin S, Wan X, Tan C. First-Line Atezolizumab for Metastatic NSCLC with High PD-L1 Expression: A United States-Based Cost-Effectiveness Analysis. Adv Ther. 2021 May;38(5):2447–57. doi: 10.1007/s12325-021-01734-6. PMID: 33821431.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c567dacbc3765cf7963fc4a0b02c2c10
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6b229a5bb536bdedc79ab1e710bbfb8a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3768ac211863b457ed994a26927a1ea8
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_39dc2d3e9eda28d9185a4462bba8dab2
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_175c4c10d3f5ae662f298aceeb5545a3
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_39c9d79d27b065f9ddd4dcac83a4bac8
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_628c9efd01ca69ed33819a9c66af271a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_baa1b89350b1f3d5a042373572357ee1
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_719a4b7e12f8aa4646b33f4cf3674e52
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f7f34a257229f1067ec453095b30ee3a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2f125e1381f5ffec4e2e7a1857eef3d2
date 2021-04-05^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://pubmed.ncbi.nlm.nih.gov/33821431
https://doi.org/10.1007/s12325-021-01734-6
isPartOf http://rdf.ncbi.nlm.nih.gov/pubchem/journal/2011
https://portal.issn.org/resource/ISSN/1865-8652
https://portal.issn.org/resource/ISSN/0741-238X
language English
source https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/
https://scigraph.springernature.com/
title First-Line Atezolizumab for Metastatic NSCLC with High PD-L1 Expression: A United States-Based Cost-Effectiveness Analysis
discusses http://id.nlm.nih.gov/mesh/M0556300
http://id.nlm.nih.gov/mesh/M0555734
http://id.nlm.nih.gov/mesh/M000618590
hasPrimarySubjectTerm http://id.nlm.nih.gov/mesh/D008175Q000188
http://id.nlm.nih.gov/mesh/D002289Q000188
hasSubjectTerm http://id.nlm.nih.gov/mesh/D014481
http://id.nlm.nih.gov/mesh/D003362
http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D019057
http://id.nlm.nih.gov/mesh/D061067
http://id.nlm.nih.gov/mesh/D060890
http://id.nlm.nih.gov/mesh/D000971
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7168
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23939

Showing number of triples: 1 to 49 of 49.